Results 151 to 160 of about 24,256 (259)

Clinical correlation analysis between vitamin A in Crohn disease combined with anemia. [PDF]

Medicine (Baltimore)
Qian K, Li P, Chen R, Wu L, Zhu Z, Li M, Dong J, Cheng Y.   +7 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

A simple MR enterography assessment of Crohn disease activity based on the most affected bowel segment: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Seo N, Lim JS, Kim SS, Bae H, Kang EA, Cheon JH.   +5 more
europepmc   +1 more source

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency

Obesity, EarlyView.
ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald   +2 more
wiley   +1 more source

Vulvar Crohn disease: A case report. [PDF]

SAGE Open Med Case Rep
Kreutz J, Jensen C, Dytoc M.
europepmc   +1 more source

Independent Risk Factors for Postoperative Intestinal Obstruction and Clinical Outcomes in Simultaneous Pancreas‐Kidney Transplantation Recipients

Organ Medicine, EarlyView.
Intestinal obstruction (IO) is an important but underexplored complication following simultaneous pancreas‐kidney transplantation (SPKT) and is associated with considerable morbidity and both clinical and economic burdens. In this single‐center cohort study, perioperative parameters, including demographic characteristics, surgical variables, and ...
Rongxin Chen, Zebin Guo, Guanghui Li, Jiali Fang, Jialin Wu, Zhuangqiang Fang, Luhao Liu, Zheng Chen   +7 more
wiley   +1 more source

Characterization of mesocolic adipose hyperplasia in a rat 2,4,6-trinitrobenzenesulfonic acid colitis model and comparison to creeping fat in Crohn disease. [PDF]

Inflamm Bowel Dis
Clua L, Suau R, Guasch M, Monfort-Ferré D, Boronat-Toscano A, Aquino M, Matute-Molina K, Jimeno M, Mañosa M, Sumoy L, Domènech E, Bartolí R, Manyé J, Serena C.   +13 more
europepmc   +1 more source

Redefining “Comorbidity” in Dermatology: Beyond Terminology, Lessons From Other Specialties

JEADV Clinical Practice, EarlyView.
Patricia Garbayo‐Salmons, Mireia Moreno   +1 more
wiley   +1 more source

Abdominoplasty for a Crohn Disease Patient Who Had a Colostomy and Significant Weight Loss After Obesity. [PDF]

Plast Reconstr Surg Glob Open
Fujita M, Tomioka Y, Furukawa S.
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source